Study guide

10.6 Breast Pathology & Clinical Breast Disease

USMLE Step 2 CK Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Human Development & Well-Patient Care

1.1 Infant, Child & Adolescent Development & Growth 1.2 Adult Development, Aging & Geriatric Assessment 1.3 Preventive Health, Immunization & Well-Patient Screening

2 Chapter 2: Immune System & Immunologic Disorders

2.1 Primary & Secondary Immunodeficiencies 2.2 Hypersensitivity Reactions, Allergy & Anaphylaxis 2.3 Autoimmune & Rheumatologic Disease Principles

3 Chapter 3: Blood & Lymphoreticular System

3.1 Anemias: Microcytic, Normocytic & Macrocytic Etiologies 3.2 Bleeding Disorders, Coagulopathies & Platelet Pathology 3.3 Hematologic Malignancies & Lymphoproliferative Disorders

4 Chapter 4: Behavioral Health & Psychiatric Disorders

4.1 Mood Disorders: Major Depression & Bipolar Spectrum 4.2 Anxiety, Trauma-Related & Somatic Symptom Disorders 4.3 Psychotic Disorders & Schizophrenia Spectrum 4.4 Substance Use Disorders & Psychopharmacology

5 Chapter 5: Nervous System & Special Senses

5.1 Cerebrovascular Disease, Stroke & Transients 5.2 Seizures, Epilepsy & Altered Mental Status 5.3 Movement Disorders, Dementia & Peripheral Neuropathies 5.4 Special Senses: Ophthalmologic & Otolaryngologic Emergencies

6 Chapter 6: Musculoskeletal System & Dermatology

6.1 Fractures, Dislocations & Orthopedic Trauma 6.2 Inflammatory Arthropathies & Crystal-Induced Diseases 6.3 Inflammatory & Infectious Dermatoses 6.4 Cutaneous Malignancies & Blistering Disorders

7 Chapter 7: Cardiovascular System

7.1 Coronary Artery Disease & Acute Coronary Syndromes 7.2 Heart Failure, Cardiomyopathies & Valvular Disease 7.3 Cardiac Arrhythmias, Conduction Blocks & EKG Interpretation 7.4 Vascular Emergencies: Aortic Aneurysms & Peripheral Arterial Disease

8 Chapter 8: Respiratory System

8.1 Obstructive Airway Diseases: Asthma & COPD 8.2 Infectious Pneumonias & Pleural Effusions 8.3 Pulmonary Vascular Disease & Thromboembolism 8.4 Acute Respiratory Distress Syndrome & Interstitial Lung Diseases

9 Chapter 9: Gastrointestinal System

9.1 Esophageal, Gastric & Peptic Ulcer Disorders 9.2 Inflammatory Bowel Disease & Colorectal Neoplasms 9.3 Hepatic Disorders, Cirrhosis & Portal Hypertension 9.4 Biliary Tract Diseases & Pancreatitis

10 Chapter 10: Renal, Urinary & Reproductive Systems

10.1 Acute Kidney Injury & Chronic Kidney Disease 10.2 Glomerular & Tubulointerstitial Diseases 10.3 Nephrolithiasis, Urinary Tract Infections & Prostate Pathology 10.4 Fluid, Electrolyte & Acid-Base Disorders 10.5 Female Reproductive Disorders & Gynecology 10.6 Breast Pathology & Clinical Breast Disease

11 Chapter 11: Pregnancy, Childbirth & Puerperium

11.1 Normal Prenatal Care & Maternal-Fetal Physiology 11.2 Medical & Obstetric Complications of Pregnancy 11.3 Labor, Delivery & Postpartum Management

12 Chapter 12: Endocrine System

12.1 Diabetes Mellitus, Hypoglycemia & Metabolic Emergencies 12.2 Thyroid & Parathyroid Disorders 12.3 Adrenal & Pituitary Axis Pathology

13 Chapter 13: Multisystem Processes & Critical Care

13.1 Shock States, Sepsis & Systemic Inflammatory Response 13.2 Environmental Emergencies, Toxicology & Overdose 13.3 Infectious Disease Principles & Systemic Pathogens

14 Chapter 14: Biostatistics, Epidemiology & Literature Interpretation

14.1 Study Designs, Bias & Validity 14.2 Diagnostic Testing: Sensitivity, Specificity, PPV & NPV 14.3 Statistical Significance, Risk Measures & Evidence-Based Medicine

15 Chapter 15: Social Sciences, Ethics & Systems-Based Practice

15.1 Medical Ethics, Informed Consent & Patient Autonomy 15.2 Legal Issues, Confidentiality & Surrogate Decision Making 15.3 Patient Safety, Quality Improvement & Medical Error Analysis 15.4 Health Care Delivery Systems, Interprofessional Care & Transitions

10.6 Breast Pathology & Clinical Breast Disease

Key Takeaways Explain This Topic AI

Breast cancer risk rises with age, BRCA1/BRCA2 mutations, atypical hyperplasia, dense breasts, early menarche, late menopause, and nulliparity; average-risk screening is biennial mammography for women aged 40–74 years per USPSTF 2024 guidance.

Suspicious breast masses warrant diagnostic mammography and ultrasound; BIRADS 4–5 lesions require tissue diagnosis with core-needle biopsy, not observation.

Invasive ductal carcinoma is the most common invasive breast cancer; hormone receptor and HER2 status guide endocrine therapy, anti-HER2 therapy, and chemotherapy decisions.

Fibroadenoma is the most common benign solid mass in young women—mobile, rubbery, well-circumscribed; simple cysts are common in peri-menopausal patients and resolve with aspiration of nonbloody fluid.

Lactational mastitis is treated with continued breastfeeding or pumping plus anti-staphylococcal antibiotics (dicloxacillin or cephalexin); fluctuance suggests abscess requiring drainage.

Last updated: July 2026

Breast Pathology in the Step 2 CK Reproductive Domain

Female reproductive content specifications include breast disorders alongside gynecologic pathology. Step 2 CK items test screening thresholds, evaluation of palpable masses, differentiation of benign versus malignant lesions, and initial cancer management guided by receptor status.

  • Breast Cancer Screening & Risk Stratification
  • Average-Risk Screening

For average-risk women, the USPSTF (2024) recommends biennial screening mammography from ages 40 to 74 years . Clinical breast examination alone is not an adequate substitute for mammography in screening-age patients.

Elevated-Risk Features

High-risk factors that alter surveillance and prevention counseling include:

  • Pathogenic BRCA1 or BRCA2 variants (also elevated ovarian cancer risk)
  • Strong family history / known hereditary cancer syndromes
  • Prior thoracic radiation (e.g., Hodgkin lymphoma treatment)
  • Atypical ductal or lobular hyperplasia; lobular carcinoma in situ (LCIS)
  • Extremely dense breasts (affects mammographic sensitivity)

High-risk patients may need earlier and more intensive imaging (annual mammography ± breast MRI) and genetic counseling referral. Risk-reducing strategies include enhanced surveillance, chemoprevention ( tamoxifen , raloxifene, or aromatase inhibitors in selected patients), and, for BRCA carriers, discussion of risk-reducing mastectomy and salpingo-oophorectomy.

  • Finding / Risk Factor Clinical Implication
  • Age 40–74, average risk Biennial mammography (USPSTF 2024)
  • BRCA1/BRCA2 pathogenic variant Genetic counseling; intensified screening; risk-reducing surgery discussion
  • Atypical hyperplasia / LCIS Increased future cancer risk; consider chemoprevention
  • Prior chest radiation Earlier screening initiation, often with MRI
  • Evaluation of a Palpable Breast Mass

Any new palpable breast mass requires age-appropriate diagnostic imaging—not routine screening protocols. [ Palpable breast mass ]

  • |
  • +--------------+--------------+
  • | |
  • [ Age <30–35 years ] [ Age ≥30–35 years ]
  • | |
  • [ Ultrasound first ] [ Diagnostic mammography + ultrasound ]
  • | |
  • v v
  • [ Simple cyst ] [ BIRADS assessment ]
  • | |
  • [ Aspiration if +----------+-----------+
  • symptomatic] | |
  • [ BIRADS 1–3 ] [ BIRADS 4–5 ]
  • | |
  • Observe / short- [ Core-needle biopsy ]
  • interval follow-up |
  • [ Pathology-guided therapy ]

BIRADS 1–2 : Benign; routine follow-up.

BIRADS 3 : Probably benign; short-interval imaging follow-up (typically 6 months).

BIRADS 4–5 : Suspicious/highly suggestive; image-guided core-needle biopsy is required.

Never rely on a "reassuring" exam alone in a patient with a persistent mass and discordant imaging.

  • Benign Breast Disease
  • Fibroadenoma

Most common benign solid breast tumor in adolescents and young women. Presents as a mobile, rubbery, well-circumscribed , nontender mass. Ultrasound shows a homogeneous, well-circumscribed solid lesion. Management is observation with serial exam/imaging if classic, or core biopsy/excision if atypical, enlarging, or patient preference.

Breast Cysts

Common in peri-menopausal women. Ultrasound distinguishes simple from complex cysts. Simple cysts with nonbloody aspirate that resolve completely are benign. Bloody aspirate, incomplete resolution, or complex cystic-solid lesions require further evaluation and biopsy.

Fibrocystic Changes

Cyclic bilateral breast pain and nodularity that fluctuate with the menstrual cycle. Supportive care includes a well-fitting bra, NSAIDs, and avoidance of unnecessary imaging for classic cyclic symptoms without dominant mass.

Intraductal Papilloma

Most common cause of unilateral bloody nipple discharge from a single duct. Evaluate with ultrasound ± mammography and duct excision for definitive diagnosis and to exclude occult malignancy.

Mastitis & Breast Abscess

Lactational mastitis typically occurs in breastfeeding patients within the first few months postpartum. Presents with unilateral breast pain, erythema, induration, and systemic symptoms (fever, malaise). Most common organism is Staphylococcus aureus .

Condition Key Features Management

Lactational mastitis Unilateral erythema/pain + fever; no fluctuance Continue breastfeeding/pumping + dicloxacillin or cephalexin ; MRSA coverage (e.g., TMP-SMX or clindamycin) if risk factors

Breast abscess Fluctuant mass, failed antibiotics, ultrasound collection Incision and drainage or ultrasound-guided aspiration + antibiotics

Inflammatory breast cancer Peau d'orange, rapid diffuse erythema, often no fever; fails antibiotics Urgent diagnostic mammography/ultrasound and skin-punch biopsy

Always counsel continued milk removal. Do not "rest" the breast. If mastitis does not improve within 48–72 hours or inflammatory features persist, reassess for abscess or inflammatory carcinoma.

  • Breast Cancer: Presentation & Initial Management
  • Histologic & Molecular Subtypes

Invasive ductal carcinoma (IDC) : Most common invasive subtype (~70–80%).

Invasive lobular carcinoma : May present with subtle findings; spreads in single-file pattern.

Ductal carcinoma in situ (DCIS) : Noninvasive; often detected as mammographic microcalcifications.

Receptor profiling (mandatory on invasive cancer) :

ER/PR positive : Endocrine therapy (tamoxifen in premenopausal; aromatase inhibitor in postmenopausal; ovarian suppression strategies in selected premenopausal high-risk patients).

HER2 positive : Anti-HER2 therapy (trastuzumab ± pertuzumab) with chemotherapy.

Triple-negative (ER−/PR−/HER2−) : Chemotherapy backbone; immunotherapy in selected early and advanced settings.

Local Therapy Principles

Early-stage disease: breast-conserving surgery ( lumpectomy ) plus radiation is equivalent to mastectomy for survival in appropriately selected patients.

Axillary staging uses sentinel lymph node biopsy for clinically node-negative disease.

Neoadjuvant systemic therapy is used for larger tumors, node-positive disease, HER2-positive, or triple-negative subtypes to enable breast conservation and assess response.

Metastatic Patterns to Remember

Breast cancer commonly metastasizes to bone, lung, liver, and brain. Bone metastases may present with pathologic fracture or hypercalcemia. New focal neurologic deficits in a patient with breast cancer history warrant urgent CNS imaging.

Clinical Decision Pearls for Exam Vignettes

A dominant mass in a woman ≥30–35 years → diagnostic mammography + ultrasound, not screening mammogram alone.

BIRADS 4–5 → core biopsy, not empirical observation.

Postpartum fever + breast erythema without fluctuance → mastitis antibiotics and continued breastfeeding.

Peau d'orange and nonresolving inflammation → consider inflammatory breast cancer and biopsy skin.

ER+/PR+ disease → endocrine therapy is a cornerstone of adjuvant treatment.

Unilateral bloody single-duct discharge → evaluate for intraductal papilloma and occult carcinoma.